
Case Discussions with the Nebraska Medicine Cancer Risk and Prevention Multidisciplinary Clinic

Kelsey Klute, MD Jessica Maxwell, MD, MSc Rachael Schmidt, DNP, FNP-C, AOCNP Jaime Malone, MS, CGC

2nd Annual Contemporary Management of Cancer Risk and Prevention Symposium February 24, 2023

WUNMC

MUNROE-MEYER



N

Cancer Risk and Prevention Multidisciplinary Clinic

Welcome to the Cancer Risk and Prevention Clinic

Our services include:

· Patient education

· Access to clinical trials in prevention

· Comprehensive risk assessment

· Genetic counseling and testing

· Physician referral services


· Prevention measures


The first of its kind in Nebraska


This comprehensive clinic is designed to care for individuals who have an increased risk of all types of cancer due to family history, medical and genetic factors, and/or lifestyle influences. Our team - who are specially trained in cancer genetics - includes providers from medical oncology, surgical ancology, gynecology, gastroenterology, endocrinology, urology, dermatology, radiology and genetics.

We are here for you and your loved ones.


Psychological services
 Screenings (mammogram, MRI, colonoscopy, blood tests, etc.)










Test Results and Interpretation POSITIVE FOR A DELETERIOUS MUTATION Itel Portamed Result 3347delAG BRCA1 3347delAG Deletarious Deletarious	est Result ngle Site BRC		
Test Parformed Result Interpretation 3347delAG BRCA1 3347delAG Deletarious	F	Test Results and Interpretat	tion
3347delAG BRCA1 3347delAG Delatar/ous This test is designed to detect the specific mutation(s) or variant(s) ind cated above. The classification and interpretation of all variants identified in this assay reflects the current state of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of aud variants may change as new scientific information becomes available. The results of this analysis are consistent with the gernline BRCA1 mutation 3347delAG, resulting in premature function of the BRCA1 protein at ermics and position 1044, Although the each rak of breast and ovarian cancer conferred by this specific mutation in the BRCA1 mutation at 44% risk of ovarian cancer y usge 70 in women (Lancel 345 ed2-85), 1994), Mutations in BRCA1 may confer as much as an 87% risk of a second breast cancer within five years of the first (Lancel 351316-321, 1998), as well as a ten-fold increase in the risk of subsequent ovarian cancer y 242, 1998). The mutation mutations in the confer a increase in the risk of subsequent ovarian cancer y 242, 1998). The mutation mutations in the confer a more as a days first of none in the years of the first (Lancel 351316-321, 1998), as well as a ten-fold increase in the risk of subsequent ovarian cancer y 242, 1998). The mutation mutation mutation mutation mutation in the results of the subsequent ovarian cancer y 243, 1998). The mutation mutation mutation mutation mutation in the subsequent ovarian cancer y 240, mutation mutatin mutation mutation mutatin mutatin mutation mutati	PO	SITIVE FOR A DELETERIOUS N	AUTATION
Identified in this assay reflects the current tates of scientific understanding at the time this report was issued. In some instances, the classification and interpretation of such variants may change as new scientific information becomes available. The results of the analysis are consistent with the gernline BRCA1 mutation 3347deIAG, resulting in premature truncation of the BRCA1 protein at amino acid position 1084. Atthough the exact rak of breast and overlar cancer conferred by this specific mutation has not been determined, studies in high-rak families indicase that detertious mutations in BRCA1 may confer as much as an 87% risk of breast cancer and a 44% risk of overlar cancer by age 70 in women (Lancet 345 362-369, 1994). Mutations in BRCA1 how been reported to confer a 20% risk of a second breast cancer within five years of the first (Lancet 351:316-321, 1998), as well as a ten-fold increase in the risk of subsequent ovarian cancer (JC 100 106:247-322, 1998). This mutation my also confer an increased (Labert My make to make treast of subsequent ovarian cancer (JC 100 106:247-322, 1998).			
chance of having this mutation. Family members can be tested for this specific mutation with a single site analysis.	Identified in this assay reflects the current a classification and interpretation of such van The results of this analysis are consistent van protein at amno acd position 1064. Althoug (detamined, studies in high-rak families nd and a 44% risk of ovarian cancer by egs of 20% risk of a second breast cancer within fi subsequent ovarian cancer (2 d7-688, 1998).	tate of oscientific underizanding at the time to and a may change as new scientific informati- inf the germline BRCA1 mutation 33/7deIA/ inf the sexicl rask of breast and overian cance case that deletenous mutations in BRCA1 m in women (Lancet 343 892-895, 1994). Mu ve years of the first (Lancet 351 316-321, 11 3:2417-2425, 1998). This mutation may also 0, as well as some other cancens. Each frat	his report was issued. In some instances, the ion becomes available. G, resulting in premature truncation of the BRCA1 er conferred by this specific mutation has not been reported as which as an 87% risk of breast cancer tations in BRCA1 have been reported to confer a 590, as well as a ten-fold increase in the risk of confer an increased (albert low) raks of mals breast tigginger failtwore this individual has a one-in-two













Diagnostic te	esting est for a personal and family histo	ory of disease	in the Genes A	lysis and deletion analyzed section	on/duplication testing of the 46 genes listed n. itary Cancers Panel
This report	t supersedes RQ490619 (10.01.20	018) and updates	the interpretation of the	below variant(:	s).
	he change in variant clas ew variant interpretation				ew of the evidence in light of
	lease note that the desig ontent may have moved		ort has changed fr	om the ori	ginal report and some of the
Updated	Interpretations				
GENE CHEK2	VARIANT c.846+4_846+7del (Intronic)	ZYCOSITY heterozygous	PRIOR VARIANT CLASSIF	ICATION	NEW VARIANT CLASSIFICATION
One Like	RESULT: POSITIVE aly Pathogenic variant ide		IEK2. CHEK2 is ass	ociated wit	h autosomal dominant
GENE	VARIANT		ZYGOSITY	VARIANT	CLASSIFICATION







Test Result MITF Pathogenic				
Cancerl	Next-Expanded® +RNAinsight®: Analyses of 77 Genes Associated with Hereditary Cancer			
RESULTS				
MITF	Pathogenic Mutation: p.E318K			
SUMMARY				
	POSITIVE: Pathogenic Mutation Detected			
INTERPRETATION				
 This individual is he 	aterozygous for the p.E318K (c.952G>A) pathogenic mutation in the MITF gene.			
 Risk estimate: up 	to a 5-fold increased risk for renal cell carcinoma (RCC) and a 2- to 8-fold increased risk for melanoma.			
 The expression and 	d severity of disease for this individual cannot be predicted.			
 Genetic testing for 	pathogenic mutations in family members can be helpful in identifying at-risk individuals.			

